Company intelligence
NeuraSignal
Eliminating Stroke with Real-Time Cerebral Blood Flow through AI and Robotics
About NeuraSignal
NeuraSignal is transforming stroke care with real-time access to cerebral blood flow, empowering clinicians to detect and prevent strokes with speed, accuracy, and automation. At the core of our mission is a bold belief: Eliminating stroke begins with real-time brain data, accessible to any provider, anywhere. Powered by AI and robotics, our flagship platform, NG2 Intelligent Ultrasound, delivers hands-free, autonomous transcranial Doppler (TCD) exams for the detection of right-to-left shunts (RLS), emboli, and cerebral vasospasm. Why it matters: up to 30% of strokes are cryptogenic, and traditional tools like TTE miss most PFOs. NG2 Intelligent Ultrasound detects 3x more PFOs than standard echo and identifies 2.7x more treatable shunts, giving clinicians the clarity to act, and patients the chance to prevent a second stroke. Fully reimbursable under existing CPT codes (93886, 93892, 93893), NG2 Intelligent Ultrasound brings diagnostic-grade neurovascular imaging to hospitals, ASCs, stroke centers, and rural clinics without relying on specialized techs. For clinicians seeking traditional, hands-on control, we also offer a manual version, the NG2 Classic Ultrasound. Beyond stroke care, our technology is proving vital across the full spectrum of traumatic brain injury (TBI). Because blood flow is fundamentally disrupted by both stroke and TBI, our systems are regularly utilized by neurocritical care teams to assess conditions ranging from mild concussions to severe, life-threatening brain injuries. Follow the NeuraSignal page and CEO Robert Hamilton for the latest updates on unlocking the power of blood flow data for stroke and TBI care.
Verified activity
Signals from NeuraSignal
9 published signals
Partnerships
NeuraSignal donated a Transcranial Doppler (TCD) system to support humanitarian aid, patient care, and physician training at Poltava State Medical University in Ukraine.
Reported by NeuraSignal
Research & Knowledge
NeuraSignal published a newsletter explaining how automated TCD supports brain care, including real-time blood flow information for TBI and ICU patients.
Reported by NeuraSignal
Research & Knowledge
NeuraSignal published a newsletter examining how its NG2 Intelligent Ultrasound and automated TCD technology can unlock real-time blood flow insights across the entire spectrum of traumatic brain injury.
Reported by NeuraSignal
Capital & Finance
NeuraSignal noted that RapidPulse, Inc. raised a $48 million Series B funding round for their suction-based technology.
Reported by Robert Hamilton, PhD
Research & Knowledge
NeuraSignal published a 2026 study from Hennepin County Medical Center showing TCD detects right-to-left shunts more reliably than TTE.
Reported by NeuraSignal
Presence & Recognition
NeuraSignal is offering both manual and robotic TCD to stroke centers across the US and Canada.
Reported by NeuraSignal
Presence & Recognition
NeuraSignal CEO Robert Hamilton, PhD broke down the findings of a 2026 study from Hennepin County Medical Center on TCD and TTE.
Reported by NeuraSignal
Partnerships
NeuraSignal donated a Transcranial Doppler (TCD) system to support humanitarian aid, patient care, and physician training at Poltava State Medical University in Ukraine.
Reported by NeuraSignal
Research & Knowledge
NeuraSignal published a video featuring David Lugo, R. EEG T. from South Shore University Hospital, explaining emboli monitoring before robotic TCD.
Reported by NeuraSignal